Cara Therapeutics (CARA)
CARA
Nephrology
BiotechSign Signal Grade
F
Signal Grade
1.2/100 composite signal score
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Insider Buying
0
Publications
100
Clinical Activity
0
Pipeline Overview
- Therapeutic Focus
- Nephrologysrc
Clinical Trial Activity
0
Clinical Trials
(ClinicalTrials.gov aggregate)
(ClinicalTrials.gov aggregate)
5
PubMed Publications
0
Catalyst Records
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Recent News & SEC Filings
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Vibrational Interventions for Sexual and Pelvic Health: A Randomized Controlled Trial. — Obstet Gynecol 2026 Aug 27 PMID 42671435
- Synthesis, Antibacterial Evaluation, and Chemometric Profiling of a Vanilloid-Based Compounds Library Active Against Helicobacter pylori. — Antibiotics (Basel) 2026 Jul 27 PMID 42650654
- Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study. — Lancet 2026 Aug 29 PMID 42628554
- Placebo Response in Randomised Controlled Trials of Systemic Therapies for Cutaneous Lupus Erythematosus: A Systematic Review and Meta-Analysis. — Pharmaceut Med 2026 Sep PMID 42611177
- Deucravacitinib 5-Year Safety and Efficacy Results in Plaque Psoriasis: A Phase 3 Open-Label Extension of Randomized Clinical Trials. — Am J Clin Dermatol 2026 Sep PMID 42563042
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Cara Therapeutics.
Full CARA Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.